Nanoparticle-Based Drug Delivery of a Poorly Bioavailable Anticancer Agent: Formulation and Pharmacokinetic Evaluation
DOI:
https://doi.org/10.5281/zenodo.22664415Keywords:
nanoparticle drug delivery, poorly bioavailable anticancer agent, PLGA nanoparticle, pharmacokinetic evaluation, enhanced permeability and retention effectAbstract
Background: Many potent anticancer agents, including taxanes and structurally related poorly soluble anticancer polyphenols,
suffer from poor aqueous solubility and correspondingly low or erratic bioavailability, and their conventional surfactant-based
formulations are associated with dose-limiting, vehicle-related toxicity. Objective: This case study synthesizes the published
formulation, characterization, in vitro release, and pharmacokinetic evidence for polymeric nanoparticle, polymeric micelle, and
liposomal delivery of a poorly bioavailable anticancer agent, using taxane-class cytotoxics as the primary worked example, to
evaluate how each stage of nanoparticle development connects to the next along the translational pathway. Methods:
Peer-reviewed formulation and pharmacokinetic studies of PLGA-based nanoparticles, PEG-PCL and Pluronic polymeric micelles,
solid lipid nanoparticles, and liposomes were identified through targeted literature searches and individually verified against
publisher records; data on particle size, zeta potential, encapsulation efficiency, in vitro release kinetics, and rodent or clinical
pharmacokinetic parameters (Cmax, AUC, relative bioavailability) were extracted and synthesized thematically. Findings:
Nanoparticle and micelle encapsulation consistently produced controlled, sustained in vitro release profiles best described by the
Korsmeyer-Peppas model, and this release behavior corresponded to substantially improved systemic exposure in vivo, with
reported area-under-the-curve increases ranging from approximately three-fold to over forty-fold relative to free drug or
conventional vehicle formulations across chemically distinct carrier platforms. Enhanced permeability and retention
(EPR)-mediated tumor accumulation was the mechanism most consistently invoked to explain improved antitumor efficacy, but
the evidence supporting reliable translation of EPR-mediated accumulation from rodent xenograft models to human solid tumors
remained markedly weaker and more heterogeneous than the pharmacokinetic evidence itself. Conclusions: Nanoparticle-based
delivery systems reliably improve the systemic pharmacokinetics of poorly bioavailable anticancer agents through mechanistically
traceable, formulation-optimizable sustained-release behavior, but confirming that this pharmacokinetic advantage translates
into clinically meaningful tumor-level drug delivery remains the central unresolved translational gap, warranting unbound-drug
quantification, more clinically representative tumor models, and combined passive-plus-active targeting strategies in future
studies.
References
Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V (2012) PLGA-based nanoparticles: an overview of biomedical applications. Journal of Controlled Release, 161(2):505-522, DOI:10.1016/j.jconrel.2012.01.043.
Attar ES, Chaudhari VH, Deokar CG, Dyawanapelly S, Devarajan PV (2023) Nano drug delivery strategies for an oral bioenhanced quercetin formulation. European Journal of Drug Metabolism and Pharmacokinetics, 48(5):495-514, DOI:10.1007/s13318-023-00843-7.
Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clinical Cancer Research, 14(13):4200-4205, DOI:10.1158/1078-0432.CCR-07-4592.
Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK (2019) Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Materials Science and Engineering: C, 98:1252-1276, DOI:10.1016/j.msec.2019.01.066.
Prabhakar U, Blakey DC, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Research, 73(8):2412-2417, DOI:10.1158/0008-5472.CAN-13-1235.
Barenholz Y (2012) Doxil - the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release, 160(2):117-134, DOI:10.1016/j.jconrel.2012.03.020.
VasanthaKumar S, Ahamed HN, Saha RN (2015) Nanomedicine I: in vitro and in vivo evaluation of paclitaxel loaded poly-(ε-caprolactone), poly(dl-lactide-co-glycolide) and poly(dl-lactic acid) matrix nanoparticles in Wistar rats. European Journal of Drug Metabolism and Pharmacokinetics, 40(2):137-161, DOI:10.1007/s13318-014-0189-6.
Jeswani G, Chablani L, Gupta U, Sahoo RK, Nakhate KT, Ajazuddin (2021) Development and optimization of paclitaxel loaded Eudragit/PLGA nanoparticles by simplex lattice mixture design: exploration of improved hemocompatibility and in vivo kinetics. Biomedicine & Pharmacotherapy, 144:112286, DOI:10.1016/j.biopha.2021.112286.
Ma P, Huang J, Liu J, Zhu Y, Chen J, Chen J, Lei L, Guan Z, Ban J, Lu Z (2023) Nanoformulation of paclitaxel: exploring the cyclodextrin/PLGA nano delivery carrier to slow down paclitaxel release, enhance accumulation in vivo. Journal of Cancer, 14(5):759-769, DOI:10.7150/jca.82410.
Sakhi M, Khan AK, Iqbal Z, Khan I, Raza A, Ullah A, Nasir F, Khan SA (2022) Design and characterization of paclitaxel-loaded polymeric nanoparticles decorated with trastuzumab for the effective treatment of breast cancer. Frontiers in Pharmacology, 13:855294, DOI:10.3389/fphar.2022.855294.
Jin MJ, Piao SJ, Jin TX, Jin ZH, Yin XZ, Gao ZG (2014) Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles. Current Medical Science, 34(1):66-75, DOI:10.1007/s11596-014-1233-0.
Liu Z, Liu D, Wang L, Zhang J, Zhang N (2011) Docetaxel-loaded Pluronic P123 polymeric micelles: in vitro and in vivo evaluation. International Journal of Molecular Sciences, 12(3):1684-1696, DOI:10.3390/ijms12031684.
Guo L, Qin X, Xue L, Yang JY, Zhang Y, Zhu S, Ye G, Tang R, Yang W (2022) A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents. Frontiers in Pharmacology, 13:964076, DOI:10.3389/fphar.2022.964076.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA (1983) Mechanisms of solute release from porous hydrophilic polymers. International Journal of Pharmaceutics, 15(1):25-35, DOI:10.1016/0378-5173(83)90064-9.
Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, Mozafari MR (2018) Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics, 10(2):57, DOI:10.3390/pharmaceutics10020057.
Yeo S, Kim MJ, Shim YK, Yoon I, Lee WK (2022) Solid lipid nanoparticles of curcumin designed for enhanced bioavailability and anticancer efficiency. ACS Omega, 7(40):35875-35884, DOI:10.1021/acsomega.2c04407.
Silvestre FA, Santos CR, Silva VDM, Ombredane AS, Pinheiro WO, Andrade LN, Garcia MP, Pacheco TJA, Joanitti GA, Luz GM, Carneiro ML (2023) Pharmacokinetics of curcumin delivered by nanoparticles and the relationship with antitumor efficacy: a systematic review. Pharmaceuticals, 16(7):943, DOI:10.3390/ph16070943.
Nel A, Ruoslahti E, Meng H (2017) New insights into "permeability" as in the enhanced permeability and retention effect of cancer nanotherapeutics. ACS Nano, 11(10):9567-9569, DOI:10.1021/acsnano.7b07214.
Khan MS, Alqahtani T, Al Shmrany H, Gupta G, Goh KW, Sahebkar A, Kesharwani P (2026) Enhanced permeability and retention (EPR) effect: advances in nanomedicine for improved tumor targeting. Biomaterials Advances, 181:214636, DOI:10.1016/j.bioadv.2025.214636.
Feng T, Wei Y, Lee RJ, Zhao L (2017) Liposomal curcumin and its application in cancer. International Journal of Nanomedicine, 12:6027-6044, DOI:10.2147/IJN.S132434.
Radha R, Paul V, Anjum S, Bouakaz A, Pitt WG, Husseini GA (2024) Enhancing curcumin's therapeutic potential in cancer treatment through ultrasound mediated liposomal delivery. Scientific Reports, 14:10499, DOI:10.1038/s41598-024-61278-x.
Fu Y, Ge Y, Yi S, Peng Q, Jiang H, Zhou J (2026) Smart nanoparticle delivery systems for curcumin: a targeted strategy to enhance anticancer efficacy and bioavailability. Journal of Materials Science: Materials in Medicine, 37(1):38, DOI:10.1007/s10856-026-07012-7.
